Oncology

Laboratory investigation in the wide field of oncology involves the study of many specific biomarkers in a variety of samples and modern cancer therapy requires the detection of specific variants in cancer associated genes.

Oxford Biosystems offers a broad product portfolio of products for oncology research and diagnostic test kits. Our products are sourced from several well-known international manufacturers and include ELISA kits, RIA kits, PCR kits, NGS products and reagents for LC-MS.

• IBL International GmbH, Germany, part of the Tecan Group
• ViennaLab Diagnostics, Austria, part of the BioVendor Group
• DIAsource Immunoassays, Belgium, part of the BioVendor Group
• BioVendor Laboratorni medicina a.s., Czechia, part of the BioVendor Group
• Biomedica Medizinprodukte GmbH, Austria
• Kamiya Biomedical Company, USA

Cancer-Associated Genes

The identification of somatic pathogenic variants in BRAF, EGFR, KRAS and NRAS genes allows targeted treatment and stratification of cancer patients. Genetic variants of genes involved in drug metabolism (eg DPYD and TMPT) can significantly alter the response to chemotherapeutic treatment.

ViennaLab Diagnostics offers highly sensitive assays to optimise cancer therapy.

• BRAF StripAssays^® identify the most relevant mutations in the BRAF gene to aid in targeted therapy in colorectal cancer, advanced non-small cell lung cancer, melanoma and thyroid cancer.
• EGFR StripAssays^® identify 30 EGFR mutations relevant for non-small cell lung cancer TKI therapies.
• KRAS and NRAS StripAssays^® identify the most relevant genetic variants of KRAS and NRAS genes interfering with monoclonal antibody treatment/therapy success in metastatic colorectal cancer.
• Fluoropyrimidines are widely used for the treatment of various solid tumors. The PGX-5FU XL StripAssay^® covers the four most clinically relevant variants in the dihydropyrimidine dehydrogenase (DPYD) gene with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020.
• Thiopurine-based therapeutic drugs may accumulate to toxic levels in patients carrying genetic variants of the drug-metabolizing enzyme TPMT. The PGX-TPMT StripAssay^® identifies the most frequent TPMT variants of therapeutic relevance.
• The ViennaLab Hereditary Cancer NGS Assay offers a complete solution comprising library preparation and proprietary bioinformatic analysis. It allows effective and streamlined variant detection of any coding mutation in 31 selected genes associated with an increased risk of hereditary cancer such as hereditary breast and ovarian cancer, Lynch Syndrome, Li-Fraumeni Syndrome, Cowden Syndrome, etc.
• The ViennaLab Somatic Mutations NGS Assay offers a complete solution comprising library preparation and proprietary bioinformatic analysis software. Focused analysis of somatic variants includes SNVs and InDels in 10 key cancer-associated genes as well as gene fusion detection in 3 cancer driver genes caused by structural variations. Some of the diseases covered by this panel are non-small cell lung cancer, colorectal cancer, melanoma, thyroid cancer, etc.

• ViennaLab Cancer Diagnostics flyer

Chromogranin A

Chromogranin A is the most important general marker for the diagnosis and clinical follow-up of neuroendocrine tumors. This marker is often elevated in patients with functionally active as well as inactive tumors. Unlike other biological markers, chromogranin A is relatively stable and largely correlates with the tumor mass.

The Tecan, IBL International GmbH Chromogranin A New Gen. ELISA is easily automated and offers improvements over previous kits including reduced incubation times, improved recovery and dilution, no hook effect up to 2 million ng/ml, and no biotin interference up to biotin concentrations of 600ng/ml.

• Tecan Chromogranin A flyer